Senior Scientist – Environmental Fate Soil Characterisation


For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary

We are seeking an experienced Soil Scientist for our Environmental Fate group located in Edinburgh


The Environmental Fate Group at Charles River Laboratories, Edinburgh tests agricultural, pharmaceutical and chemical products in support of their registration in accordance with international regulations.  Test systems including soil, sediment and natural water are used routinely and these systems require to have their physical/chemical characteristics analytically determined in accordance with Good Laboratory Practice.  A vacancy exists for a scientist who has experience of the physical/chemical testing of soil, sediment and water systems, including particle size distribution, organic carbon, cation exchange capacity, total nitrogen and phosphorous, total hardness.


The following are minimum requirements related to the Scientist-Soil Analysis and Characterisation position.


The successful candidate will be involved in the importation, characterisation and maintenance of test systems, and expanding the service provided.  Educated to at least degree level in a relevant scientific discipline, the person will be a self-starter able to operate independently. Excellent communication skills and customer service are essential to this role.


The salary for this position will be dependant on the candidate’s skills and experience.


The closing date for this position will be Thursday, 01 October 2020.


About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased  to $2.62 billion.


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.